Yttrium (90Y) tacatuzumab tetraxetan
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | α-fetoprotein |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6470H9971N1712O2007S4290Y |
Molar mass | 145 kg/mol |
(what is this?) (verify) |
Yttrium (90Y) tacatuzumab tetraxetan is an investigational humanized monoclonal antibody intended for the treatment of cancer.[1] The antibody itself, tacatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90,[2] a radioisotope which destroys the tumour cells.
References
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council". 4 September 2004. Archived from the original on 2004-09-11.
- ^ WHO Drug Information
Categories:
- Articles with short description
- Short description is different from Wikidata
- Drugs not assigned an ATC code
- Articles with changed CASNo identifier
- Chemicals that do not have a ChemSpider ID assigned
- Infobox drug articles with non-default infobox title
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Drugs that are a monoclonal antibody
- Monoclonal antibodies for tumors
- Antibody-drug conjugates
- Radiopharmaceuticals
- Yttrium compounds
- Experimental cancer drugs
- DOTA (chelator) derivatives
- All stub articles
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
- Nuclear medicine stubs